undamentalytics Newsletter
Sign in

Docgo Inc. (DCGO) stock

Add to watchlist

Add holding +

NASDAQ: DCGO Nasdaq Health Care Services Next results ~November 9, 2026

C Fundamentals grade

Docgo Inc. is a US-listed company in the health care services industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$0.8

Revenue-to-maturity cash-flow model

Base case. Range ~$0.8–$1.0 across our lower- and higher-growth cases (0%–5% a year).

Price vs value

No Buy/Hold/Sell rating is issued: only 2 valuation models apply; a rating needs 3.

Docgo Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 1 selling0 purchases and 1 sale by directors and officers, last 12 monthsInsider trades
  • Funds64 adding, 59 cuttingOf 20 active managers that changed their stake, 11 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Docgo files

Where Docgo stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $295m, down 32.4% on a year earlier, a smaller fall than the 42.0% decline a quarter earlier. That puts it 34 of 34 for growth among the health care services companies we cover. Free-cash-flow margin fell to -8.8% from 18.4% a year earlier. Operating margin narrowed to -62.2% from -6.6%. The diluted share count is down 7.1% on a year earlier, which lifts each remaining share. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 6 of our 7 financial-health checks. Our revenue-to-maturity cash-flow model value is $0.75 a share, against a share price of $0.28.

Source: 10-Q filed August 17, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 9, 2026 (estimated)

Docgo Inc.'s trailing-twelve-month revenue fell 32.4% year on year, with a free-cash-flow margin of -8.8%. Where it stands out: long-term debt as % of assets of 0.1% ranks 1 of 31 health care services companies we cover. Where it lags: revenue growth of -32.4% ranks 40 of 41 health care services companies we cover.

Current signal Net margin compressing: TTM net margin fell to -65.3%, down 61.1pp year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Shrinking share count. Diluted shares fell 7.1% in a year, so each share owns more of the business.

Things to watch

  • Results due soon. Results are expected around 9 November; the share price can move sharply on the day.
  • Revenue shrinking. Revenue fell 32.4% over the last 12 months.
  • Loss-making. Operating margin is -62.2%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 55.5 points on a year ago.
  • Burning cash. Free cash flow was -8.8% of revenue over the last 12 months.
  • Volatile shares. Over the past year the shares showed annualised volatility of 85% and a beta of 1.6 against the S&P 500.

Latest results: FY2026 Q2

Filed August 17, 2026
Earnings per share
-$0.26 against an average estimate of -$0.15: missed by 69.8%
Revenue
$73m, down 8.7% on a year earlier
Share reaction
-28.8% in the first session after the results on August 17, 2026, against -1.1% for the S&P 500
Guidance given
full-year 2026 revenue $305m to $310m (Full-year 2026); adjusted EBITDA $-22m to $-17m (Full-year 2026)
Next report
November 9, 2026; average EPS estimate -$0.13

Docgo's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-13.4%
  • 1 week-24.9%
  • 1 month-42.2%
  • This year-75.6%
  • 1 year-80.4%
  • 5 years-97.9%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$295M
Operating margin
-62.2%
Net margin
-65.3%
EPS (TTM, diluted)
$-1.96

Growth

Revenue growth
−32.4%
Change in growth rate
+9.6 pts
Share count change
−7.1%

Cash

Free cash flow (TTM)
-$25.8M
FCF margin
-8.8%
Stock pay % of revenue
4.6%

Earnings

Last results
August 17, 2026
Next results (est.)
November 9, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Agreement
  2. Results
  3. Guidance

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Docgo Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: only 2 valuation models apply; a rating needs 3.

Valuation models

We value Docgo Inc. as an operating company, with every model that fits that kind of business. Cost of equity 8.5%: the 10-year Treasury yield (4.9%) plus a beta of 0.78 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$0.8 ~$0.8–$1.0 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$0.1 ~$1.4–$7.0 Included, half weight
Combined value Weighted average of the models that apply: the primary model (revenue-to-maturity model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$0.6 ~$0.1–$0.8 2 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Docgo Inc. with Health Care Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 202020212022202320242025Now
Share price$10.15$9.35$7.07$5.59$4.24$0.88$0.21
Market value$593m$887m$728m$590m$464m$87m$21m
+ Net debt (− = net cash)−$31m−$173m−$155m−$34m−$59m−$51m−$25m
Enterprise value$562m$714m$573m$556m$405m$36m−$4m
Multiples
Price / sales 6.3x2.8x1.7x0.9x0.8x0.3x0.1x
Price / earnings —37.4x21.1x86.1x23.2x——
Price / free cash flow ——28.4x—7.0x2.9x—
EV / EBITDA —40.4x17.7x17.7x9.1x——

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

18 /100

Weak moat

How hard Docgo's competitive advantage looks for rivals to wear away, judged from 5 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median 2.0% of total assets over 5 years.

  • Durability 10 / 20

    Operating margin has been a median -0.2%; its worst year was -62.2%.

  • Cash conversion 4 / 20

    Free cash flow was positive in 2 of 5 years, at a median -5.4% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (24 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 9, 2026, after the close. Analysts expect revenue of $77m and EPS of −$0.13 (range −$0.15 to −$0.11) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.79 +56% $307m −5%
Next $0.14 +118% $326m +6%

Next year's EPS estimate has moved −23.8% in 90 days, across 2 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +86.9% on 90 days ago. In the last 30 days, 0 analysts raised Docgo Inc.'s forecast and 1 cut it.

Consensus EPS forecast Docgo Inc., last 90 days
−$1.00 −$0.50 $0.00 $0.50 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.42 Current fiscal year, 60 days ago: −$0.42 Current fiscal year, 30 days ago: −$0.42 Current fiscal year, 7 days ago: −$0.42 Current fiscal year, Now: −$0.79 −$0.79 Next fiscal year, 90 days ago: $0.19 Next fiscal year, 60 days ago: $0.19 Next fiscal year, 30 days ago: $0.19 Next fiscal year, 7 days ago: $0.19 Next fiscal year, Now: $0.14 $0.14

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.42$0.19
60 days ago −$0.42$0.19
30 days ago −$0.42$0.19
7 days ago −$0.42$0.19
Now −$0.79$0.14

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.15 −$0.26 −69.8%
Mar 2026 −$0.06 −$0.33 −463.8%
Dec 2025 −$0.34 −$1.68 −390.0%
Sept 2025 −$0.40 −$0.25 +38.5%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 17, 2026
  • Full-year 2026 revenue Full-year 2026 $305m to $310m Narrowed
    “Full-year 2026 revenue range is narrowed to $305-$310 million, compared to the Company's prior guidance of $300-$315 million.” source
  • Adjusted EBITDA Full-year 2026 $-22m to $-17m Non-GAAP Lowered
    “Full-year 2026 adjusted EBITDA 2 is expected to be ($17-$22) million, compared to the Company's prior guidance of ($5-$10) million.” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

Analyst recommendations

5 analysts, Oct 2026
Buy240%
Hold360%
Sell00%

Monthly trend

  1. Oct 20261135
  2. Sep 20261135
  3. Aug 20261135

Counts of recommendations published by analysts covering Docgo Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
2.0%
of tradable shares
Days to cover
3.12
at average volume
Short interest, 1 month
−28%
to October 15, 2026
Held by institutions
36%
of shares
Held by insiders
3.1%
of shares
Employees
2,537
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −80.4%

$1.09 on October 31, 2025 to $0.21

ThenNowEffect
Revenue (last 12 months) $436m $295m −32.4%
P/S multiple 0.3x 0.1x −73.0%
Share count 106m 98m +7.7%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years −96.5%

$6.04 on November 3, 2023 to $0.21

ThenNowEffect
Revenue (last 12 months) $452m $295m −34.7%
P/S multiple 1.4x 0.1x −95.0%
Share count 107m 98m +9.0%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
DCGO−8%−24%−21%−24%−79%−76%
Industry peers (median)−1%−28%+8%−6%−6%+15%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
DCGO58%42%42%50%25%27%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
DCGO−30%−45%−54%−49%−84%−77%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since December 17, 2020: 98% from October 13, 2022 to November 2, 2026. Getting back needed a 5087% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.21 – $1.11
From 52-week high
−80.7%
vs 50-day average
−37.3%
vs 200-day average
−62.3%
Volatility (1 year)
85%
Beta vs S&P 500
1.57

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
7 up, 5 down
typical move ±14.7%
After a week
6 up, 6 down
typical move ±15.7%
After a month
5 up, 7 down
typical move ±18.3%
Results releasedNext dayS&P 500 next day5 days21 days
August 17, 2026 −28.8% −1.1% −42.7% −42.9%
May 11, 2026 +4.4% +0.1% −3.0% −2.5%
March 16, 2026 +18.4% +1.3% +2.6% −19.3%
November 10, 2025 −0.9% +1.8% −13.2% −11.7%
August 7, 2025 +11.3% +0.7% +15.6% +11.3%
May 8, 2025 −41.7% +0.6% −41.7% −33.3%
February 27, 2025 −23.9% −0.1% −27.8% −35.0%
November 7, 2024 +9.6% +1.2% +14.5% +12.9%
August 7, 2024 +18.2% +1.6% +5.9% +18.2%
May 8, 2024 −13.6% +0.6% −5.6% −12.6%
February 28, 2024 +4.1% +0.2% +1.0% +3.3%
January 16, 2024 +1.2% −0.9% +14.6% +16.2%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Docgo Inc. in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Docgo Inc.
$200M $400M $600M $800M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $533.8M Revenue (TTM), FY23 Q4: $624.3M Revenue (TTM), FY24 Q1: $703.4M Revenue (TTM), FY24 Q2: $742.8M Revenue (TTM), FY24 Q3: $695M Revenue (TTM), FY24 Q4: $616.6M Revenue (TTM), FY25 Q1: $520.5M Revenue (TTM), FY25 Q2: $436M Revenue (TTM), FY25 Q3: $368.1M Revenue (TTM), FY25 Q4: $322.2M Revenue (TTM), FY26 Q1: $301.7M Revenue (TTM), FY26 Q2: $294.7M $294.7M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $533.8M
FY23 Q4 $624.3M
FY24 Q1 $703.4M
FY24 Q2 $742.8M
FY24 Q3 $695M
FY24 Q4 $616.6M
FY25 Q1 $520.5M
FY25 Q2 $436M
FY25 Q3 $368.1M
FY25 Q4 $322.2M
FY26 Q1 $301.7M
FY26 Q2 $294.7M
Revenue growth, TTM YoY Docgo Inc.
-50% 0% 50% 100% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 17.8% Revenue growth, TTM YoY, FY23 Q4: 41.7% Revenue growth, TTM YoY, FY24 Q1: 61.5% Revenue growth, TTM YoY, FY24 Q2: 64.5% Revenue growth, TTM YoY, FY24 Q3: 30.2% Revenue growth, TTM YoY, FY24 Q4: -1.2% Revenue growth, TTM YoY, FY25 Q1: -26.0% Revenue growth, TTM YoY, FY25 Q2: -41.3% Revenue growth, TTM YoY, FY25 Q3: -47.0% Revenue growth, TTM YoY, FY25 Q4: -47.7% Revenue growth, TTM YoY, FY26 Q1: -42.0% Revenue growth, TTM YoY, FY26 Q2: -32.4% -32.4%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 17.8%
FY23 Q4 41.7%
FY24 Q1 61.5%
FY24 Q2 64.5%
FY24 Q3 30.2%
FY24 Q4 -1.2%
FY25 Q1 -26.0%
FY25 Q2 -41.3%
FY25 Q3 -47.0%
FY25 Q4 -47.7%
FY26 Q1 -42.0%
FY26 Q2 -32.4%
Operating margin (TTM) Docgo Inc.
-80% -60% -40% -20% 0% 20% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: 0.6% Operating margin (TTM), FY23 Q4: 2.4% Operating margin (TTM), FY24 Q1: 5.4% Operating margin (TTM), FY24 Q2: 6.2% Operating margin (TTM), FY24 Q3: 6.9% Operating margin (TTM), FY24 Q4: 4.7% Operating margin (TTM), FY25 Q1: -0.2% Operating margin (TTM), FY25 Q2: -6.6% Operating margin (TTM), FY25 Q3: -22.0% Operating margin (TTM), FY25 Q4: -55.3% Operating margin (TTM), FY26 Q1: -60.6% Operating margin (TTM), FY26 Q2: -62.2% -62.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 0.6%
FY23 Q4 2.4%
FY24 Q1 5.4%
FY24 Q2 6.2%
FY24 Q3 6.9%
FY24 Q4 4.7%
FY25 Q1 -0.2%
FY25 Q2 -6.6%
FY25 Q3 -22.0%
FY25 Q4 -55.3%
FY26 Q1 -60.6%
FY26 Q2 -62.2%
FCF margin (TTM) Docgo Inc.
-20% -10% 0% 10% 20% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -15.1% FCF margin (TTM), FY23 Q4: -12.8% FCF margin (TTM), FY24 Q1: -9.4% FCF margin (TTM), FY24 Q2: -5.4% FCF margin (TTM), FY24 Q3: 5.5% FCF margin (TTM), FY24 Q4: 9.6% FCF margin (TTM), FY25 Q1: 15.2% FCF margin (TTM), FY25 Q2: 18.4% FCF margin (TTM), FY25 Q3: 14.6% FCF margin (TTM), FY25 Q4: 9.3% FCF margin (TTM), FY26 Q1: 5.5% FCF margin (TTM), FY26 Q2: -8.8% -8.8%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -15.1%
FY23 Q4 -12.8%
FY24 Q1 -9.4%
FY24 Q2 -5.4%
FY24 Q3 5.5%
FY24 Q4 9.6%
FY25 Q1 15.2%
FY25 Q2 18.4%
FY25 Q3 14.6%
FY25 Q4 9.3%
FY26 Q1 5.5%
FY26 Q2 -8.8%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 94 319 441 624 617 322 295
Gross profit — −133 −83 — — — —
EBITDA −9 18 32 31 45 −162 −170
Operating income −15 15 22 15 29 −178 −183
Net income −15 24 35 7 20 −182 −192
Diluted EPS −$0.25 $0.25 $0.34 $0.06 $0.18 −$1.84 −$1.96
Growth (year on year)
Revenue — +238.7% +38.2% +41.7% −1.2% −47.7% −32.4%
EBITDA — — +83.3% −2.8% +41.6% −464.3% —
Operating income — — +42.2% −31.0% +90.6% −720.6% —
Net income — — +45.7% −80.2% — <−999% —
Diluted EPS — — +36.0% −82.4% — <−999% —
Margins
Gross margin — −41.7% −18.9% — — — —
EBITDA margin −9.8% 5.5% 7.4% 5.0% 7.2% −50.4% −57.7%
Operating margin −15.7% 4.8% 5.0% 2.4% 4.7% −55.3% −62.2%
Net margin −15.7% 7.4% 7.9% 1.1% 3.2% −56.6% −65.3%
Free-cash-flow margin −16.0% −2.1% 5.8% −11.5% 10.8% 9.3% −8.8%
Cash flow
Cash from operations −11 −2 29 −64 70 34 −23
Capital spending 4 5 3 7 4 5 3
Free cash flow −15 −7 26 −72 67 30 −26
Stock-based pay — 1 8 21 14 17 14
Free cash flow after stock pay — −8 18 −93 53 12 −39
Balance sheet
Cash 32 176 157 59 89 51 25
Total debt 1 3 3 25 30 0 0
Net debt (negative = net cash) −31 −173 −155 −34 −59 −51 −25
Diluted shares 58m 95m 103m 106m 109m 99m 98m
Returned to shareholders
Buybacks — 0 4 0 14 11 0
Total returned — 0 4 0 14 11 0

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

6 of 7 checks passed · June 30, 2026
What it owns · $187m
Short-term assets $120mLonger-term assets $67m
What it owes, and who funded it · $210m
Short-term liabilities $72mLonger-term liabilities $19mShareholders' equity $119m
  • Short-term assets cover short-term liabilities $120m of assets due within a year against $72m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $120m short-term assets against $19m of longer-dated liabilities.
  • More cash than debt $25m of cash against $207,373 of debt.
  • Debt below 40% of shareholders' equity Debt is 0% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 1% to 0% over five years.
  • A year's operating cash flow covers at least 20% of debt −$23m of operating cash flow against $207,373 of debt.
  • Operating profit covers interest at least five times over No material interest expense reported.

From Docgo Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2026 Q2 TTM
Buybacks (TTM)
$0
Returned to shareholders
0%
of free cash flow
Buybacks, last 3 fiscal years
$24.6M
Diluted share count
−7.1%
year over year
Total shareholder yield
0.0%
dividends 0.0% + buybacks 0.0% of market value
R&D spending
4.8%
of revenue

Competitors: side by side with peers

Closest by revenue in health care services
Last 12 months unless stated DCGO VMD DLHC SBC CDNA PETS Median
Revenue, last 12 months $295m $302m $254m $175m $497m $169m $1.2bn
Revenue growth, last 12 months −32.4% 25.2% −29.5% −6.9% 38.9% −20.3% 7.3%
Revenue growth, 3-year average −13.3% 24.5% −9.5% — 18.7% −13.0% 11.3%
Revenue growth, latest quarter −8.7% 23.9% −46.9% 13.4% 39.3% −19.9% 8.5%
Gross margin — 57.5% 24.3% 71.9% 65.5% 27.9% 27.9%
Operating margin −62.2% 7.5% −0.1% 37.3% 23.4% −18.2% 2.3%
Operating margin, 3-year average −20.8% 7.9% 3.5% 37.3% −4.4% −12.6% 2.3%
Net margin −65.3% 4.8% −8.5% 28.0% 25.9% −17.3% 1.2%
Cash from operations / revenue −7.7% 20.2% 5.5% 35.9% 13.9% −14.1% 6.1%
Free-cash-flow margin −8.8% 9.7% 5.5% 35.3% 10.3% −16.4% 5.1%
Free-cash-flow margin, 3-year average 1.4% 4.1% 6.6% — 5.3% −7.3% 3.6%
Stock pay / revenue 4.6% 3.0% 0.5% — 7.7% 0.6% 1.1%
Change in share count −7.1% −1.6% 2.2% 1.4% −9.3% 2.9% 0.3%

Median of all 41 companies we cover in health care services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

41 health care services companies
Measure Company Peer median Rank
Revenue growth Growth -32.4% 7.3% 40 of 41
Change in growth rate Growth +9.6pp +1.1pp 4 of 41
Operating margin Profitability -62.2% 2.6% 37 of 40
Net margin Profitability -65.3% 1.2% 38 of 41
Free-cash-flow margin Cash generation -8.8% 5.1% 35 of 40
Stock pay as % of revenue Cash generation 4.6% 0.9% 28 of 35
Long-term debt as % of assets Balance sheet 0.1% 27.7% 1 of 31
Change in share count Balance sheet -7.1% 0.4% 4 of 39

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Segments
Line of business Revenue Share YoY
Transportation Services $201M 62.3% ▲ 3.8%
Mobile Health Services $121M 37.7% ▼ 71.3%
Corporate $0 0.0% —
Geography
Region Revenue Share YoY
United States $268M 83.3% ▼ 52.0%
United Kingdom $53.9M 16.7% ▼ 6.6%

From Docgo Inc.'s 10-K filed March 16, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$19.7M
Institutions reporting
119
Shares held vs prior quarter
▼ 9.4%
Positions opened / closed
26 / 27

Top buyers and sellers, Q2 2026: 64 institutions bought and 59 sold ; the biggest buyer was Peapod Lane Capital LLC (+1.4M shares) and the biggest seller Blackrock, Inc (−4.9M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Vanguard Capital Management LLC $1.9M 3.7M 9.8% ▲ 1.2%
P.A.W. Capital Corp $1.8M 3.5M 9.2% ▲ 16.6%
Knott David M Jr $1.4M 2.7M 7.0% 0.0%
Peapod Lane Capital LLC $1.3M 2.5M 6.6% ▲ 121.4%
Citadel Advisors LLC $1.2M 2.4M 6.2% ▼ 5.9%
Renaissance Technologies LLC $1.2M 2.3M 5.9% ▲ 49.3%
S Squared Technology, LLC $1.1M 2.1M 5.4% 0.0%
Acadian Asset Management LLC $918,000 1.8M 4.7% ▲ 17.8%
AQR Capital Management LLC $881,994 1.7M 4.5% ▲ 132.4%
Moore Capital Management, LP $756,087 1.5M 3.8% 0.0%
Blackrock, Inc. $750,442 1.5M 3.8% ▼ 77.2%
Isthmus Partners, LLC $615,179 1.2M 3.1% ▲ 17.7%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Docgo Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $15,334 1 trade by 1 insider · 0% under pre-set plans
Net ▼ $15,334 net selling
Insider Date Trade Shares Price Value
Tendler Ely D General Counsel and Secretary December 15, 2025 Sell 16,850 $0.91 $15,334

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 9, 2026 estimated from the company's past filing pattern, not announced

  • August 17, 2026
  • May 11, 2026
  • March 16, 2026
  • November 10, 2025
  • August 7, 2025
  • May 8, 2025

Recent SEC filings

Data status

When each part of this page on Docgo Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Docgo Inc. in brief

What does Docgo Inc. do?
Docgo Inc. is a US-listed company in the health care services industry. Its financial year ends in December.
What is Docgo Inc.'s stock ticker?
Docgo Inc. trades under the ticker DCGO on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Docgo Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Docgo Inc. reported revenue of $295M, 32.4% lower than a year earlier, according to its SEC filings.
What is Docgo Inc.'s free cash flow?
Docgo Inc.'s free-cash-flow margin is -8.8% of revenue over the trailing twelve months, ranking 35 of the 40 health care services companies we cover.
Who are Docgo Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Vanguard Capital Management LLC, P.A.W. Capital Corp and Knott David M Jr. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Docgo Inc. buying back stock, and does it pay a dividend?
Docgo Inc. spent $0 on share repurchases over the trailing twelve months, and its diluted share count fell 7.1% over the year.
What is Docgo Inc.'s market cap?
On November 2, 2026, Docgo Inc.'s market capitalisation was about $21M and net debt of -$25M. Market figures come from third-party market data and may be delayed.
How much debt does Docgo Inc. have?
Docgo Inc.'s debt-to-equity ratio is 0.2%, from its latest balance sheet (0.6% five years earlier). The financial health section below sets out its other solvency checks.
Who are Docgo Inc.'s competitors?
In our Health Care Services peer group, the companies closest to Docgo Inc. are Viemed Healthcare, Inc., DLH Holdings Corp., SBC Medical Group Holdings Inc, Caredx, Inc. and Petmed Express Inc. The side-by-side comparison below sets their revenue, margins and growth against Docgo Inc.'s.
Are insiders buying or selling Docgo Inc. stock?
Over the last 12 months, Docgo Inc.'s directors and officers reported 0 open-market purchases and 1 sales on Form 4. The insider trading page charts every trade.
When is Docgo Inc.'s next earnings date?
Around November 9, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Docgo Inc. announces its own schedule.